Evaluation of CD206 agonists in diabetic retinopathy

这种称为糖尿病视网膜病变的疾病源于糖尿病对视网膜血管的损害。这是美国最常见的糖尿病眼病，也是导致失明的主要原因。在疾病的早期阶段没有可用的治疗方法，这种疾病通常也没有症状。该项目旨在评估CD206激动剂预防或逆转与糖尿病视网膜病变相关的纤维化的能力，糖尿病视网膜病变是导致失明的主要原因。 在此期间，研究小组评估了几种CD206激动剂(多肽和小分子)在Uemara博士开发的糖尿病视网膜病变小鼠模型中的活性。最初的体内实验显示，在减少眼睛炎症和预防纤维化方面，结果令人振奋。

The condition called diabetic retinopathy stems from damage to the blood vessels of the retina caused by diabetes. This is the most common diabetic eye disease and a leading cause of blindness in the United States. No treatment is available in the early stages of the disease, which also frequently have no symptoms. This project seeks to evaluate the capacity of CD206 agonists to prevent or reverse fibrosis associated with diabetic retinopathy, a leading cause of blindness. During this period the team evaluated the activity of several CD206 agonists (peptide and small molecule) in a mouse model of diabetic retinopathy developed by Dr. Uemara. Initial in vivo experiments showed promising results with a reduction of inflammation and prevention of fibrosis in the eye.